Celgene Cp Cvr (CELGZ) 1.46 $CELGZ
Acceleron and Celgene Announce Updated Results from an Ongoing Phase 2 Study of Luspatercept in Beta-Thalassemia Presented at the 21st Congress of the European Hematology Association
BusinessWire - Fri Jun 10, 6:00AM CDT
--in patients with beta-thalassemia -
XLRN: 35.44 (+0.94), CELGZ: 1.46 (-0.04)
Acceleron and Celgene Announce Updated Results from an Ongoing Phase 2 Study of Luspatercept in Myelodysplastic Syndromes at the 21st Congress of the European Hematology Association
BusinessWire - Fri Jun 10, 6:00AM CDT
--- Acceleron to host conference call and live webcast today at 8:00 a.m. EDT (2:00 p.m. CEST) -
XLRN: 35.44 (+0.94), CELGZ: 1.46 (-0.04), CELG: 102.91 (-3.22)
Celgene Announces Presentations of Investigational Studies in Blood Cancers at EHA 2016
BusinessWire - Thu Jun 09, 6:30AM CDT
Celgene Corporation (NASDAQ:CELG) today announced that more than 40 presentations reporting on investigational studies in blood cancers will be presented during the 21st European Hematology Association annual meeting in Copenhagen, Denmark, from June 9-12, 2016.
CELG: 102.91 (-3.22), CELGZ: 1.46 (-0.04)
Study Reveals Racial Disparities in Multiple Myeloma Treatment Patterns
BusinessWire - Tue Jun 07, 3:05PM CDT
Celgene Corporation (NASDAQ:CELG) today announced the presentation of a study comparing treatment patterns, healthcare costs and overall survival between African American and Caucasian Medicare beneficiaries with newly diagnosed multiple myeloma. The study, which was presented by Dr. Sikander Ailawadhi of the Mayo Clinic at a poster session during the 52nd ASCO Annual Meeting in Chicago, Ill, discussed disparities observed in treatment initiation between the two studied populations and the impact of these disparities on patient outcomes.
CELG: 102.91 (-3.22), CELGZ: 1.46 (-0.04)
Data Presented at ASCO 2016 Builds upon Foundation of Abraxane(R) Plus Gemcitabine as a First-Line Treatment in Patients with Metastatic Pancreatic Cancer
BusinessWire - Sat Jun 04, 4:32PM CDT
Celgene Corporation (NASDAQ:CELG) today announced that results from multiple sponsored and independent studies presented during the 52nd ASCO Annual Meeting evaluated the use of ABRAXANE(R) (paclitaxel protein-bound particles for injectable suspension)(albumin-bound) in combination with gemcitabine in first-line metastatic pancreatic cancer.
CELG: 102.91 (-3.22), CELGZ: 1.46 (-0.04)
Pooled Data from Meta-Analysis Suggest Significant Overall Survival Benefit of Investigational REVLIMID(R) Maintenance Following Autologous Stem Cell Transplant in Multiple Myeloma
BusinessWire - Fri Jun 03, 3:59PM CDT
Celgene Corporation (NASDAQ:CELG) today announced data from a meta-analysis of overall survival in multiple myeloma (MM) patients receiving investigational maintenance treatment with REVLIMID(R) (lenalidomide) capsules following high-dose melphalan and autologous stem cell transplant (ASCT) were presented during the 52nd ASCO Annual Meeting in Chicago, Illinois. The analysis, based on data from studies conducted by the Alliance for Clinical Trials in Oncology (formerly Cancer and Leukemia Group
with support from the National Cancer Institute, Intergroupe Francophone du Myelome (IFM) and the Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA), was presented by Dr. Philip McCarthy of Roswell Park Cancer Institute and lead investigator of the CALGB (Alliance) 100104 study. The findings demonstrated significantly prolonged overall survival (OS) compared to the control arm of placebo or no maintenance.
CELG: 102.91 (-3.22), CELGZ: 1.46 (-0.04)
Mylan Launches Generic Vidaza® Injection
PR Newswire - Thu Jun 02, 6:30AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Azacitidine for Injection, 100 mg/vial, which is a generic version of Celgene's Vidaza® Injection, 100 mg/vial. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product. Azacitidine for Injection is a nucleoside metabolic inhibitor indicated for the treatment of the five French-American-British (FAB) subtypes of myelodysplastic syndrome, a blood cell disorder that can occur as a result of cancer treatments or can progress to leukemia.
MYL: 44.53 (-1.23), CELGZ: 1.46 (-0.04)
The Newly Launched IL-17 Inhibitor Cosentyx is Gradually Gaining Momentum in the EU5, While Established Subcutaneous TNF-Alpha Inhibitors Humira and Enbrel Continue to Dominate Biologics Patient Share in Psoriasis
PR Newswire - Wed Jun 01, 9:08AM CDT
Decision Resources Group finds that in the EU5, while surveyed dermatologists prefer subcutaneous TNF-alpha inhibitors AbbVie's Humira and Amgen/Pfizer's Enbrel for first-line treatment, Janssen Biotech's Stelara is also seeing increasing use in earlier-lines of therapy, driven by favorable efficacy and safety, increasing physician familiarity and convenient dosing. Among the biologics, Humira is the patient share leader, followed by Enbrel and Stelara. However, Novartis's Cosentyx, the first-in-class IL-17 inhibitor, has steadily captured market share as it gradually becomes available to dermatologists in the EU5. Celgene's Otezla, an oral PDE-4 inhibitor, is seeing only limited usage in moderate and severe patients probably because its access is limited across the EU5. However, unlike biologics, it is seeing comparable use in both the moderate and severe sub-populations.
NVS: 78.94 (-1.57), CELGZ: 1.46 (-0.04)
InvestorsObserver releases covered-call reports for GoPro, Verizon Communications, Vertex Pharmaceuticals, NVIDIA and Celgene
PR Newswire - Tue May 31, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GPRO, VZ, VRTX, NVDA and CELG.
GPRO: 10.26 (-0.64), VRTX: 91.49 (-1.00), VZ: 52.67 (+0.72), NVDA: 46.20 (-1.18), CELGZ: 1.46 (-0.04), CELG: 102.91 (-3.22)
Ulcerative Colitis - Pipeline Review, H1 2016 - Key Players Include Amgen, Gilead Sciences & Celgene Corporation - Research and Markets
BusinessWire - Fri May 27, 4:43AM CDT
Research and Markets has announced the addition of the "Ulcerative Colitis - Pipeline Review, H1 2016" report to their offering.
GILD: 84.45 (-1.32), CELGZ: 1.46 (-0.04)
TriNetX Enters into Collaboration with Celgene Corporation to Advance Clinical Trial Design and Research for Next-Generation Medicines
PR Newswire - Tue May 24, 12:00PM CDT
TriNetX, a leader in international clinical research networks, today announced a collaboration with Celgene Corporation to advance clinical trial design and research for Celgene's next-generation therapeutic programs.
CELGZ: 1.46 (-0.04)
COTA Increases Cross-Industry Support With the Addition of Celgene, Foundation Medicine, Inc., HealthScape Advisors and Novartis as Strategic Investors
Marketwire Canada - Tue May 24, 8:01AM CDT
Leading Health Care Informatics Company Gains Mission Momentum Across Health Care Discovery, Development, Delivery and Payment Sectors
FMI: 18.91 (-1.17), NVS: 78.94 (-1.57), CELGZ: 1.46 (-0.04)
Celgene Corporation to Webcast at Upcoming Investor Conferences
BusinessWire - Fri May 20, 6:30AM CDT
Celgene Corporation (NASDAQ:CELG) plans to present at three upcoming investor conferences where Celgene management will provide an overview of the Company. The conferences will be webcast live and the webcast will be available in the Investor Relations section of the Company's website at www.celgene.com.
CELG: 102.91 (-3.22), CELGZ: 1.46 (-0.04)
Celgene, Yahoo!, American Airlines, Exxon Mobil, and Skyworks Solutions and more offer option-trading opportunities that offer returns of more than 20%
PR Newswire - Thu May 19, 9:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CELG, YHOO, AAL, XOM and SWKS.
YHOO: 36.83 (-0.52), SWKS: 65.55 (-2.42), XOM: 89.98 (-0.69), AAL: 33.14 (-0.26), CELGZ: 1.46 (-0.04), CELG: 102.91 (-3.22)
Global Ulcerative Colitis Market CAGR Growth of 6.6% by 2020 - Trends, Technologies & Opportunities Report 2016-2020 - Key Vendors: Amgen, Celgene, Eisai
GlobeNewswire - Thu May 19, 8:21AM CDT
Research and Markets has announced the addition of the "Global Ulcerative Colitis Market 2016-2020" report to their offering.
AMGN: 154.78 (-2.00), CELGZ: 1.46 (-0.04)
Celgene Announces Presentations of Investigational Studies in Solid Tumor and Blood Cancers at ASCO 2016
BusinessWire - Wed May 18, 4:43PM CDT
Celgene Corporation (NASDAQ:CELG) today announced more than 65 presentations reporting on investigational studies in blood and solid tumor cancers will be presented during the 52ndAmerican Society of Clinical Oncology meeting in Chicago, Ill. from June 3-7, 2016.
CELG: 102.91 (-3.22), CELGZ: 1.46 (-0.04)
Agios and Celgene Establish New Collaboration in Metabolic Immuno-Oncology and Amend Certain Rights from 2010 Agreement
GlobeNewswire - Tue May 17, 3:01PM CDT
- New Collaboration Builds on Agios Research Platform and Leverages Celgene Capabilities; Agios to Receive $200 Million Upfront Payment -
AGIO: 50.35 (-5.87), CELG: 102.91 (-3.22), CELGZ: 1.46 (-0.04)
Agenovir Completes $10.6 Million Series A Financing
PR Newswire - Tue May 17, 8:00AM CDT
Agenovir Corporation, a company using computationally engineered nuclease technology to develop novel antiviral therapeutics, today announced that it raised $10.6 million in a Series A financing. The round was led by Data Collective with participation from Celgene Corporation, Lightspeed Venture Partners and several prominent individual and other investors.
CELGZ: 1.46 (-0.04)
Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Pipeline Review, H1 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Celgene Corp, Gilead Sciences, Novartis - Research and Markets
BusinessWire - Wed May 11, 1:24PM CDT
Research and Markets has announced the addition of the "Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H1 2016" report to their offering.
GILD: 84.45 (-1.32), NVS: 78.94 (-1.57), CELGZ: 1.46 (-0.04)
Acceleron and Celgene Announce Updated Results from an Ongoing Phase 2 Study of Luspatercept in Beta-Thalassemia Presented at the 21st Congress of the European Hematology Association
BusinessWire - Fri Jun 10, 6:00AM CDT
--in patients with beta-thalassemia -
XLRN: 35.44 (+0.94), CELGZ: 1.46 (-0.04)
Acceleron and Celgene Announce Updated Results from an Ongoing Phase 2 Study of Luspatercept in Myelodysplastic Syndromes at the 21st Congress of the European Hematology Association
BusinessWire - Fri Jun 10, 6:00AM CDT
--- Acceleron to host conference call and live webcast today at 8:00 a.m. EDT (2:00 p.m. CEST) -
XLRN: 35.44 (+0.94), CELGZ: 1.46 (-0.04), CELG: 102.91 (-3.22)
Celgene Announces Presentations of Investigational Studies in Blood Cancers at EHA 2016
BusinessWire - Thu Jun 09, 6:30AM CDT
Celgene Corporation (NASDAQ:CELG) today announced that more than 40 presentations reporting on investigational studies in blood cancers will be presented during the 21st European Hematology Association annual meeting in Copenhagen, Denmark, from June 9-12, 2016.
CELG: 102.91 (-3.22), CELGZ: 1.46 (-0.04)
Study Reveals Racial Disparities in Multiple Myeloma Treatment Patterns
BusinessWire - Tue Jun 07, 3:05PM CDT
Celgene Corporation (NASDAQ:CELG) today announced the presentation of a study comparing treatment patterns, healthcare costs and overall survival between African American and Caucasian Medicare beneficiaries with newly diagnosed multiple myeloma. The study, which was presented by Dr. Sikander Ailawadhi of the Mayo Clinic at a poster session during the 52nd ASCO Annual Meeting in Chicago, Ill, discussed disparities observed in treatment initiation between the two studied populations and the impact of these disparities on patient outcomes.
CELG: 102.91 (-3.22), CELGZ: 1.46 (-0.04)
Data Presented at ASCO 2016 Builds upon Foundation of Abraxane(R) Plus Gemcitabine as a First-Line Treatment in Patients with Metastatic Pancreatic Cancer
BusinessWire - Sat Jun 04, 4:32PM CDT
Celgene Corporation (NASDAQ:CELG) today announced that results from multiple sponsored and independent studies presented during the 52nd ASCO Annual Meeting evaluated the use of ABRAXANE(R) (paclitaxel protein-bound particles for injectable suspension)(albumin-bound) in combination with gemcitabine in first-line metastatic pancreatic cancer.
CELG: 102.91 (-3.22), CELGZ: 1.46 (-0.04)
Pooled Data from Meta-Analysis Suggest Significant Overall Survival Benefit of Investigational REVLIMID(R) Maintenance Following Autologous Stem Cell Transplant in Multiple Myeloma
BusinessWire - Fri Jun 03, 3:59PM CDT
Celgene Corporation (NASDAQ:CELG) today announced data from a meta-analysis of overall survival in multiple myeloma (MM) patients receiving investigational maintenance treatment with REVLIMID(R) (lenalidomide) capsules following high-dose melphalan and autologous stem cell transplant (ASCT) were presented during the 52nd ASCO Annual Meeting in Chicago, Illinois. The analysis, based on data from studies conducted by the Alliance for Clinical Trials in Oncology (formerly Cancer and Leukemia Group
with support from the National Cancer Institute, Intergroupe Francophone du Myelome (IFM) and the Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA), was presented by Dr. Philip McCarthy of Roswell Park Cancer Institute and lead investigator of the CALGB (Alliance) 100104 study. The findings demonstrated significantly prolonged overall survival (OS) compared to the control arm of placebo or no maintenance. CELG: 102.91 (-3.22), CELGZ: 1.46 (-0.04)
Mylan Launches Generic Vidaza® Injection
PR Newswire - Thu Jun 02, 6:30AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Azacitidine for Injection, 100 mg/vial, which is a generic version of Celgene's Vidaza® Injection, 100 mg/vial. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product. Azacitidine for Injection is a nucleoside metabolic inhibitor indicated for the treatment of the five French-American-British (FAB) subtypes of myelodysplastic syndrome, a blood cell disorder that can occur as a result of cancer treatments or can progress to leukemia.
MYL: 44.53 (-1.23), CELGZ: 1.46 (-0.04)
The Newly Launched IL-17 Inhibitor Cosentyx is Gradually Gaining Momentum in the EU5, While Established Subcutaneous TNF-Alpha Inhibitors Humira and Enbrel Continue to Dominate Biologics Patient Share in Psoriasis
PR Newswire - Wed Jun 01, 9:08AM CDT
Decision Resources Group finds that in the EU5, while surveyed dermatologists prefer subcutaneous TNF-alpha inhibitors AbbVie's Humira and Amgen/Pfizer's Enbrel for first-line treatment, Janssen Biotech's Stelara is also seeing increasing use in earlier-lines of therapy, driven by favorable efficacy and safety, increasing physician familiarity and convenient dosing. Among the biologics, Humira is the patient share leader, followed by Enbrel and Stelara. However, Novartis's Cosentyx, the first-in-class IL-17 inhibitor, has steadily captured market share as it gradually becomes available to dermatologists in the EU5. Celgene's Otezla, an oral PDE-4 inhibitor, is seeing only limited usage in moderate and severe patients probably because its access is limited across the EU5. However, unlike biologics, it is seeing comparable use in both the moderate and severe sub-populations.
NVS: 78.94 (-1.57), CELGZ: 1.46 (-0.04)
InvestorsObserver releases covered-call reports for GoPro, Verizon Communications, Vertex Pharmaceuticals, NVIDIA and Celgene
PR Newswire - Tue May 31, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GPRO, VZ, VRTX, NVDA and CELG.
GPRO: 10.26 (-0.64), VRTX: 91.49 (-1.00), VZ: 52.67 (+0.72), NVDA: 46.20 (-1.18), CELGZ: 1.46 (-0.04), CELG: 102.91 (-3.22)
Ulcerative Colitis - Pipeline Review, H1 2016 - Key Players Include Amgen, Gilead Sciences & Celgene Corporation - Research and Markets
BusinessWire - Fri May 27, 4:43AM CDT
Research and Markets has announced the addition of the "Ulcerative Colitis - Pipeline Review, H1 2016" report to their offering.
GILD: 84.45 (-1.32), CELGZ: 1.46 (-0.04)
TriNetX Enters into Collaboration with Celgene Corporation to Advance Clinical Trial Design and Research for Next-Generation Medicines
PR Newswire - Tue May 24, 12:00PM CDT
TriNetX, a leader in international clinical research networks, today announced a collaboration with Celgene Corporation to advance clinical trial design and research for Celgene's next-generation therapeutic programs.
CELGZ: 1.46 (-0.04)
COTA Increases Cross-Industry Support With the Addition of Celgene, Foundation Medicine, Inc., HealthScape Advisors and Novartis as Strategic Investors
Marketwire Canada - Tue May 24, 8:01AM CDT
Leading Health Care Informatics Company Gains Mission Momentum Across Health Care Discovery, Development, Delivery and Payment Sectors
FMI: 18.91 (-1.17), NVS: 78.94 (-1.57), CELGZ: 1.46 (-0.04)
Celgene Corporation to Webcast at Upcoming Investor Conferences
BusinessWire - Fri May 20, 6:30AM CDT
Celgene Corporation (NASDAQ:CELG) plans to present at three upcoming investor conferences where Celgene management will provide an overview of the Company. The conferences will be webcast live and the webcast will be available in the Investor Relations section of the Company's website at www.celgene.com.
CELG: 102.91 (-3.22), CELGZ: 1.46 (-0.04)
Celgene, Yahoo!, American Airlines, Exxon Mobil, and Skyworks Solutions and more offer option-trading opportunities that offer returns of more than 20%
PR Newswire - Thu May 19, 9:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CELG, YHOO, AAL, XOM and SWKS.
YHOO: 36.83 (-0.52), SWKS: 65.55 (-2.42), XOM: 89.98 (-0.69), AAL: 33.14 (-0.26), CELGZ: 1.46 (-0.04), CELG: 102.91 (-3.22)
Global Ulcerative Colitis Market CAGR Growth of 6.6% by 2020 - Trends, Technologies & Opportunities Report 2016-2020 - Key Vendors: Amgen, Celgene, Eisai
GlobeNewswire - Thu May 19, 8:21AM CDT
Research and Markets has announced the addition of the "Global Ulcerative Colitis Market 2016-2020" report to their offering.
AMGN: 154.78 (-2.00), CELGZ: 1.46 (-0.04)
Celgene Announces Presentations of Investigational Studies in Solid Tumor and Blood Cancers at ASCO 2016
BusinessWire - Wed May 18, 4:43PM CDT
Celgene Corporation (NASDAQ:CELG) today announced more than 65 presentations reporting on investigational studies in blood and solid tumor cancers will be presented during the 52ndAmerican Society of Clinical Oncology meeting in Chicago, Ill. from June 3-7, 2016.
CELG: 102.91 (-3.22), CELGZ: 1.46 (-0.04)
Agios and Celgene Establish New Collaboration in Metabolic Immuno-Oncology and Amend Certain Rights from 2010 Agreement
GlobeNewswire - Tue May 17, 3:01PM CDT
- New Collaboration Builds on Agios Research Platform and Leverages Celgene Capabilities; Agios to Receive $200 Million Upfront Payment -
AGIO: 50.35 (-5.87), CELG: 102.91 (-3.22), CELGZ: 1.46 (-0.04)
Agenovir Completes $10.6 Million Series A Financing
PR Newswire - Tue May 17, 8:00AM CDT
Agenovir Corporation, a company using computationally engineered nuclease technology to develop novel antiviral therapeutics, today announced that it raised $10.6 million in a Series A financing. The round was led by Data Collective with participation from Celgene Corporation, Lightspeed Venture Partners and several prominent individual and other investors.
CELGZ: 1.46 (-0.04)
Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Pipeline Review, H1 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Celgene Corp, Gilead Sciences, Novartis - Research and Markets
BusinessWire - Wed May 11, 1:24PM CDT
Research and Markets has announced the addition of the "Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H1 2016" report to their offering.
GILD: 84.45 (-1.32), NVS: 78.94 (-1.57), CELGZ: 1.46 (-0.04)
